Skip to content

Latest medicine updates

103 updates found

New New Updated Updated Retired Retired

NARROW IT DOWN

MEDICINE NAME

CHANGES

Date range

DOCUMENT TYPE

STATUS

Pil
selexipag,
Updated 21-Feb-17
Updated
  • Change to section 6 - date of revision
Pil
choriogonadotropin alfa
Updated 21-Feb-17
Updated
  • Change to section 3 - how to take/use
Pil
golimumab,
Updated 21-Feb-17
Updated
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
Pil
golimumab,
Updated 21-Feb-17
Updated
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
Pil
golimumab,
Updated 21-Feb-17
Updated
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
SPC
golimumab,
Updated 21-Feb-17
Updated
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text
SPC
golimumab,
Updated 21-Feb-17
Updated
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
Pil
paracetamol, caffeine, codeine phosphate hemihydrate
Updated 21-Feb-17
New
  • New PIL for eMC ie a PIL for an existing product but one that is new to the eMC
Pil
naproxen, esomeprazole magnesium trihydrate,
Updated 21-Feb-17
Updated
  • Change to section 1 - what the product is
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 5 - how to store or dispose
  • Change to section 6 - what the product looks like and pack contents
  • Improved presentation of PIL
Pil
olmesartan medoxomil
Updated 21-Feb-17
New
  • New PIL for new product
SPC
paracetamol
Updated 21-Feb-17
Updated
  • Change to section 1 - Name of the medicinal product
SPC
formoterol fumarate dihydrate, , aclidinium bromide,
Updated 21-Feb-17
Updated
  • Change to section 4.8 - Undesirable effects
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text
SPC
amiodarone hydrochloride
Updated 21-Feb-17
Updated
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
SPC
benzydamine hydrochloride
Updated 21-Feb-17
Updated
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text
SPC
desferrioxamine mesilate,
Updated 21-Feb-17
Updated
  • Change to section 4.2 - Posology and method of administration
SPC
hydrochlorothiazide, amiloride hydrochloride
Updated 21-Feb-17
Updated
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.2 - Pharmacokinetic properties
SPC
meningococcal group-B vaccine (rDNA, component, adsorbed),
Updated 21-Feb-17
Updated
  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text
SPC
hydrochlorothiazide, amiloride hydrochloride
Updated 21-Feb-17
Updated
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.2 - Pharmacokinetic properties
SPC
norethisterone
Updated 21-Feb-17
Updated
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects - how to report a side effect
Pil
NIQUITIN Pre-Quit 4 mg Mint Lozenges
nicotine
Retired 21-Feb-17
Omega Pharma Ltd
Retired
  • Product/presentation currently not marketed
SPC
atenolol
Updated 21-Feb-17
Updated
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
SPC
atenolol
Updated 21-Feb-17
Updated
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
SPC
atenolol
Updated 21-Feb-17
Updated
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
SPC
imatinib mesilate,
Updated 21-Feb-17
New
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
SPC
imatinib mesilate,
Updated 21-Feb-17
New
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
Pil
benzydamine hydrochloride
Updated 21-Feb-17
Updated
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
Pil
amiodarone hydrochloride
Updated 21-Feb-17
Updated
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
Pil
apixaban,
Updated 21-Feb-17
Updated
  • Change to section 3 - how to take/use
  • Change to section 6 - date of revision
Pil
apixaban,
Updated 21-Feb-17
Updated
  • Change to section 3 - how to take/use
  • Change to section 6 - date of revision
Pil
zonisamide
Updated 21-Feb-17
Updated
  • Correction of spelling/typing errors
Pil
baricitinib,
Updated 20-Feb-17
New
  • New PIL for new product
Pil
ribavirin, tribavirin
Updated 20-Feb-17
Updated
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision
Pil
formoterol fumarate dihydrate, , aclidinium bromide,
Updated 20-Feb-17
Updated
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
Pil
human fibrinogen,
Updated 20-Feb-17
New
  • New PIL for new product
Pil
quetiapine fumarate,
Updated 20-Feb-17
Updated
  • Change to section 2 - what you need to know - warnings and precautions
SPC
bendamustine hydrochloride monohydrate,
Updated 20-Feb-17
Updated
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
Pil
acetylcholine chloride
Updated 20-Feb-17
Updated
  • Change to section 6 - manufacturer
Pil
venlafaxine hydrochloride,
Updated 20-Feb-17
Updated
  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - use in children/adolescents
  • Change to section 2 - excipient warnings
  • Change to section 3 - dose and frequency
  • Change to section 6 - date of revision
SPC
atorvastatin calcium trihydrate,
Updated 20-Feb-17
Updated
  • Change to section 1 - Name of the medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.8 - Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.6 - Special precautions for disposal and other handling
Pil
ataluren,
Updated 20-Feb-17
Updated
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - date of revision
SPC
bendamustine hydrochloride,
Updated 20-Feb-17
Updated
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects - how to report a side effect
SPC
testosterone
Updated 20-Feb-17
Updated
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text
SPC
sulpiride
Updated 20-Feb-17
New
  • New individual SPC (was previously included in joint SPC)
SPC
sulpiride
Updated 20-Feb-17
New
  • New individual SPC (was previously included in joint SPC)
SPC
human fibrinogen,
Updated 20-Feb-17
New
  • New SPC for new product
SPC
lomustine
Updated 20-Feb-17
Updated
  • Change to section 7 - Marketing authorisation holder
  • Change to section 6.5 - Nature and contents of container
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.1 - List of excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Fertility, pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
Pil
cetrorelix acetate,
Updated 20-Feb-17
Updated
  • Change to section 4 - how to report a side effect
  • Change to other sources of information section
Pil
choriogonadotropin alfa
Updated 20-Feb-17
Updated
  • Change to section 4 - how to report a side effect
  • Change to other sources of information section
Pil
choriogonadotropin alfa
Updated 20-Feb-17
Updated
  • Change to section 4 - how to report a side effect
  • Change to other sources of information section
Pil
lutropin alfa
Updated 20-Feb-17
Updated
  • Change to section 4 - how to report a side effect
  • Change to other sources of information section

Page 1 of 3 Next

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue